Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock rose 7% Monday following positive Phase 2 trial results for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), a ...
Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) up 6.5% since last earnings report: Can it continue?
It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 6.5% in that time frame, outperforming the S&P 500. But investors have to be ...
By combining the language of groups with that of geometry and linear algebra, Marius Sophus Lie created one of math’s most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback